Ultrasensitive Nanopore Sensing of Mucin 1 and Circulating Tumor Cells in Whole Blood of Breast Cancer Patients by Analyte-Triggered Triplex-DNA Release
Ke Sun,Piaopiao Chen,Shixin Yan,Weidan Yuan,Yu Wang,Xinqiong Li,Linqin Dou,Changjian Zhao,Jianfu Zhang,Qiang Wang,Zhoukai Fu,Long Wei,Zhaodan Xin,Zhuoyun Tang,Yichen Yan,Yiman Peng,Binwu Ying,Jie Chen,Jia Geng
DOI: https://doi.org/10.1021/acsami.1c03538
2021-04-27
Abstract:The characterization of circulating tumor cells (CTCs) by liquid biopsy has a great potential for precision medicine in oncology. Here, a universal and tandem logic-based strategy is developed by combining multiple nanomaterials and nanopore sensing for the determination of mucin 1 protein (MUC1) and breast cancer CTCs in real samples. The strategy consists of analyte-triggered signal conversion, cascaded amplification via nanomaterials including copper sulfide nanoparticles (CuS NPs), silver nanoparticles (Ag NPs), and biomaterials including DNA hydrogel and DNAzyme, and single-molecule-level detection by nanopore sensing. The amplification of the non-DNA nanomaterial gives this method considerable stability, significantly lowers the limit of detection (LOD), and enhances the anti-interference performance for complicated samples. As a result, the ultrasensitive detection of MUC1 could be achieved in the range of 0.0005–0.5 pg/mL, with an LOD of 0.1 fg/mL. Moreover, we further tested MUC1 as a biomarker for the clinical diagnosis of breast cancer CTCs under double-blind conditions on the basis of this strategy, and MCF-7 cells could be accurately detected in the range from 5 to 2000 cells/mL, with an LOD of 2 cells/mL within 6 h. The detection results of the 19 clinical samples were highly consistent with those of the clinical pathological sections, nuclear magnetic resonance imaging, and color ultrasound. These results demonstrate the validity and reliability of our method and further proved the feasibility of MUC1 as a clinical diagnostic biomarker for CTCs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.1c03538?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.1c03538</a>.Experimental section; different structures of Cu<sup>2+</sup>-catalyzed triplex DNAzyme; DNA sequences employed in this work; typical current trace of single-molecule recording in all experimental and control groups; scatter plots and histograms showing blockages and dwell times by different DNAzyme I, DNAzyme II, and DNAzyme III; optimization of assay condition including nanopore <i>trans</i>-voltage, volume of CuS NPs, cation exchange reaction time, Cu<sup>2+</sup>-reaction time, and incubation time for MUC1 disintegration of DNA hydrogel; gel electrophoresis of DNAzyme-Cu<sup>2+</sup> reaction; statistical data of measuring CTCs with nanopore; and clinical data of pathological sections (100×) (<a class="ext-link" href="/doi/suppl/10.1021/acsami.1c03538/suppl_file/am1c03538_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.
materials science, multidisciplinary,nanoscience & nanotechnology